IL150480A0 - A NOVEL-CRYSTALLINE FORM OF N-[4-[2-(2-AMINO-4, 7-DIHYDRO-4-OXO-3H-PYRROLO[2, 3-d]PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID AND PROCESS THEREFOR - Google Patents

A NOVEL-CRYSTALLINE FORM OF N-[4-[2-(2-AMINO-4, 7-DIHYDRO-4-OXO-3H-PYRROLO[2, 3-d]PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID AND PROCESS THEREFOR

Info

Publication number
IL150480A0
IL150480A0 IL15048001A IL15048001A IL150480A0 IL 150480 A0 IL150480 A0 IL 150480A0 IL 15048001 A IL15048001 A IL 15048001A IL 15048001 A IL15048001 A IL 15048001A IL 150480 A0 IL150480 A0 IL 150480A0
Authority
IL
Israel
Prior art keywords
pyrrolo
pyrimidin
dihydro
benzoyl
oxo
Prior art date
Application number
IL15048001A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22679017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL150480(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL150480A0 publication Critical patent/IL150480A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
IL15048001A 2000-02-25 2001-02-12 A NOVEL-CRYSTALLINE FORM OF N-[4-[2-(2-AMINO-4, 7-DIHYDRO-4-OXO-3H-PYRROLO[2, 3-d]PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID AND PROCESS THEREFOR IL150480A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18496400P 2000-02-25 2000-02-25
PCT/US2001/001229 WO2001062760A2 (fr) 2000-02-25 2001-02-12 Nouvelle forme cristalline de n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-acide glutamique et procede correspondant

Publications (1)

Publication Number Publication Date
IL150480A0 true IL150480A0 (en) 2002-12-01

Family

ID=22679017

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15048001A IL150480A0 (en) 2000-02-25 2001-02-12 A NOVEL-CRYSTALLINE FORM OF N-[4-[2-(2-AMINO-4, 7-DIHYDRO-4-OXO-3H-PYRROLO[2, 3-d]PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID AND PROCESS THEREFOR
IL150480A IL150480A (en) 2000-02-25 2002-06-27 Crystalline form of acid N - [4 - [2 - (2 - amino - 7,4 - dihydro - 4 - oxo - H3 - pyrrolo [d – 2,3] pyrimidine - 5 - il) ethyl] benzoyl] -L - Glutemic and a process for its preparation

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL150480A IL150480A (en) 2000-02-25 2002-06-27 Crystalline form of acid N - [4 - [2 - (2 - amino - 7,4 - dihydro - 4 - oxo - H3 - pyrrolo [d – 2,3] pyrimidine - 5 - il) ethyl] benzoyl] -L - Glutemic and a process for its preparation

Country Status (36)

Country Link
US (1) US7138521B2 (fr)
EP (1) EP1259513B1 (fr)
JP (1) JP4846158B2 (fr)
KR (1) KR100744917B1 (fr)
CN (1) CN1183135C (fr)
AR (1) AR029471A1 (fr)
AT (1) ATE249462T1 (fr)
AU (1) AU777047B2 (fr)
BR (1) BR0108604A (fr)
CA (1) CA2400155C (fr)
CO (1) CO5261585A1 (fr)
CZ (1) CZ303772B6 (fr)
DE (1) DE60100750T2 (fr)
DK (1) DK1259513T3 (fr)
DZ (1) DZ3283A1 (fr)
EA (1) EA004684B1 (fr)
EG (1) EG24073A (fr)
ES (1) ES2206403T3 (fr)
HK (1) HK1051856A1 (fr)
HR (1) HRP20020701B1 (fr)
HU (1) HU229704B1 (fr)
IL (2) IL150480A0 (fr)
MX (1) MXPA02008242A (fr)
MY (1) MY124784A (fr)
NO (1) NO323422B1 (fr)
NZ (1) NZ519796A (fr)
PE (1) PE20011082A1 (fr)
PL (1) PL208061B1 (fr)
PT (1) PT1259513E (fr)
SI (1) SI1259513T1 (fr)
SK (1) SK287375B6 (fr)
SV (1) SV2002000321A (fr)
TW (1) TWI237024B (fr)
UA (1) UA72791C2 (fr)
WO (1) WO2001062760A2 (fr)
ZA (1) ZA200205265B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100364993C (zh) * 2003-05-30 2008-01-30 江苏恒瑞医药股份有限公司 培美曲噻盐及其制备方法
CN100364994C (zh) * 2004-11-25 2008-01-30 重庆医药工业研究院有限责任公司 培美曲塞二钠的一种新晶型及其制备方法
EP1942907A2 (fr) * 2005-11-04 2008-07-16 Merck and Co., Inc. Procedes d'utilisation de saha et d'erlotinibe aux fins de traitement du cancer
US20070197473A1 (en) * 2005-11-04 2007-08-23 Frankel Stanley R Methods of using SAHA and Bortezomib for treating cancer
EP1934226A2 (fr) 2006-08-14 2008-06-25 Sicor, Inc. Diacide de pemetrexed de haute pureté et ses procédés de préparation
DE602007010894D1 (de) * 2006-08-14 2011-01-13 Sicor Inc Tellungsverfahren dafür
EP1943252B1 (fr) * 2006-08-14 2010-12-22 Sicor, Inc. Procédés de préparation de sels pharmaceutiquement acceptables lyophilisés de diacide de pemetrexed
KR101101443B1 (ko) 2006-08-14 2012-01-03 시코르, 인크. 페메트렉세드의 중간체의 제조 방법
CA2667348A1 (fr) * 2006-11-03 2008-05-15 University Of Maryland, Baltimore Procedes d'utilisation de saha et de bortezomibe destines a traiter un myelome multiple
EP2129674A2 (fr) 2007-04-03 2009-12-09 Dr. Reddy's Laboratories Ltd. Formes solides de pemetrexed
CN101417998B (zh) * 2007-10-24 2012-10-24 重庆医药工业研究院有限责任公司 一种培美曲塞盐的纯化方法
US20090181990A1 (en) * 2007-12-23 2009-07-16 Patel Nileshkumar S Stable amorphous form of pemetrexed disodium
EP2334685A4 (fr) * 2008-09-08 2011-10-26 Reddys Lab Ltd Dr Disodium de pemetrexed amorphe
WO2010030598A2 (fr) * 2008-09-11 2010-03-18 Dr. Reddy's Laboratories Limited Formulations pharmaceutiques comprenant du pemetrexed
CN101684121B (zh) * 2008-09-22 2013-04-03 重庆医药工业研究院有限责任公司 培美曲塞二酸的新晶型及其制备方法
CN102050825B (zh) * 2009-11-05 2014-12-17 上海创诺制药有限公司 制备培美曲塞二钠2.5水结晶的方法
US9174991B2 (en) 2009-11-24 2015-11-03 Azad Pharmaceutical Ingredients Ag Crystalline form of pemetrexed disodium
CN102372719B (zh) * 2010-08-26 2013-10-30 齐鲁制药有限公司 培美曲塞二甲酯对甲苯磺酸盐晶型及其制备方法
KR101069128B1 (ko) * 2011-03-10 2011-09-30 건일제약 주식회사 페메트렉시드 또는 그의 염을 포함하는 항산화제-비함유 주사용 용액 형태의 약학적 제제의 제조방법
US9051322B2 (en) 2011-03-23 2015-06-09 Scinopharm Taiwan, Ltd. Process for the production of a pemetrexed salt
EP2688888B1 (fr) * 2011-03-25 2017-06-14 Scinopharm Taiwan, Ltd. Procédé pour la production de disodium pémétrexed
ITRM20120398A1 (it) 2012-08-08 2014-02-09 Berlin Chemie Ag Procedimento di sintesi pemetrexed e suo sale di lisina.
CN102911176B (zh) * 2012-10-10 2015-07-22 德州德药制药有限公司 一种培美曲塞二钠的制备方法
WO2014060959A1 (fr) * 2012-10-17 2014-04-24 Shilpa Medicare Limited Procédé de préparation de dipotassium de pemetrexed cristallin
US20150359898A1 (en) 2013-02-06 2015-12-17 Cipla Limited Pemetrexed Complexes and Pharmaceutical Compositions Containing Pemetrexed Complexes
US20160051679A1 (en) 2013-04-12 2016-02-25 Actavis Group Ptc Ehf. Pemetrexed Formulation
KR101485243B1 (ko) 2013-05-08 2015-01-21 씨제이헬스케어 주식회사 안정화된 페메트렉시드 제제
JP6094388B2 (ja) * 2013-06-07 2017-03-15 ニプロ株式会社 ペメトレキセドを含む注射用組成物
US20160145260A1 (en) 2013-06-14 2016-05-26 Synthon B.V. Stable pemetrexed arginine salt and compositions comprising it
WO2015008221A1 (fr) 2013-07-16 2015-01-22 Dr. Reddy’S Laboratories Limited Nouvelles formes cristallines de sels de trométhamine de pemetrexed
WO2015050230A1 (fr) 2013-10-03 2015-04-09 富士フイルム株式会社 Préparation pharmaceutique d'injection, et procédé de fabrication de celle-ci
NZ630292A (en) * 2013-11-25 2015-02-27 Shilpa Medicare Ltd Process for crystalline pemetrexed dipotassium salt
NZ630299A (en) 2014-06-30 2014-11-28 Shilpa Medicare Ltd Pemetrexed dipotassium formulations
CA2962383C (fr) 2014-10-30 2019-10-08 Scinopharm Taiwan, Ltd. Formes cristallines du diacide de pemetrexed et leurs procedes de production
CN105566328B (zh) * 2014-11-06 2018-04-24 博瑞生物医药（苏州）股份有限公司 培美曲塞二酸多晶型的制备方法
PL3804686T3 (pl) * 2017-10-10 2023-12-11 Sun Pharmaceutical Industries Ltd Dożylna infuzyjna postać dawkowania dla pemetreksedu

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO169490C (no) * 1988-03-24 1992-07-01 Takeda Chemical Industries Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolopyrimidinderivater
KR0162654B1 (ko) * 1989-12-11 1998-11-16 알렌 제이. 시니스갤리 N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체
US5416211A (en) * 1992-09-25 1995-05-16 Eli Lilly And Company Process for preparing 5-substituted pyrrolo-[2,3-d]pyrimidines
WO1998008382A1 (fr) * 1996-08-30 1998-03-05 Eli Lilly And Company Antifoliques non classiques de pyrrolo[2,3-d]pyrimidine
TR200001220T2 (tr) * 1997-09-26 2001-05-21 Eli Lilly And Company Antifolatlar yapmak için yararlı işlemler ve aramaddeler.
ZA987550B (en) * 1997-09-26 2000-02-21 Lilly Co Eli Processes and intermediates useful to make antifolates.
WO2001014379A2 (fr) * 1999-08-23 2001-03-01 Eli Lilly And Company Nouvelle forme cristalline de disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]-pyrimidin-5-yl)ethyl]benzoyl]-l- sel d'acide glutamique et procedes de preparation

Also Published As

Publication number Publication date
US20030216416A1 (en) 2003-11-20
DE60100750T2 (de) 2004-07-29
PT1259513E (pt) 2004-02-27
PE20011082A1 (es) 2001-10-22
DK1259513T3 (da) 2004-01-12
ES2206403T3 (es) 2004-05-16
HUP0204232A3 (en) 2006-01-30
AU777047B2 (en) 2004-09-30
KR100744917B1 (ko) 2007-08-01
DZ3283A1 (fr) 2001-08-30
NO323422B1 (no) 2007-04-30
DE60100750D1 (de) 2003-10-16
JP2003530321A (ja) 2003-10-14
KR20020075449A (ko) 2002-10-04
US7138521B2 (en) 2006-11-21
CA2400155A1 (fr) 2001-08-30
CZ303772B6 (cs) 2013-05-02
MY124784A (en) 2006-07-31
EP1259513A2 (fr) 2002-11-27
CN1406238A (zh) 2003-03-26
ATE249462T1 (de) 2003-09-15
HU229704B1 (en) 2014-05-28
MXPA02008242A (es) 2002-11-29
AU3445101A (en) 2001-09-03
TWI237024B (en) 2005-08-01
SV2002000321A (es) 2002-07-16
HUP0204232A2 (hu) 2003-04-28
SI1259513T1 (en) 2003-12-31
SK11862002A3 (sk) 2003-01-09
NZ519796A (en) 2003-01-31
CO5261585A1 (es) 2003-03-31
JP4846158B2 (ja) 2011-12-28
CN1183135C (zh) 2005-01-05
SK287375B6 (sk) 2010-08-09
ZA200205265B (en) 2003-11-11
PL208061B1 (pl) 2011-03-31
EP1259513B1 (fr) 2003-09-10
EG24073A (en) 2008-05-11
AR029471A1 (es) 2003-07-02
EA004684B1 (ru) 2004-06-24
WO2001062760A2 (fr) 2001-08-30
HRP20020701B1 (en) 2011-02-28
CA2400155C (fr) 2009-09-15
HRP20020701A2 (en) 2003-12-31
CZ20022875A3 (cs) 2003-02-12
EA200200905A1 (ru) 2003-02-27
BR0108604A (pt) 2002-11-19
IL150480A (en) 2007-12-03
UA72791C2 (uk) 2005-04-15
HK1051856A1 (en) 2003-08-22
NO20023974D0 (no) 2002-08-21
PL356423A1 (en) 2004-06-28
WO2001062760A3 (fr) 2001-12-06
NO20023974L (no) 2002-08-21

Similar Documents

Publication Publication Date Title
IL150480A0 (en) A NOVEL-CRYSTALLINE FORM OF N-[4-[2-(2-AMINO-4, 7-DIHYDRO-4-OXO-3H-PYRROLO[2, 3-d]PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID AND PROCESS THEREFOR
AU6890800A (en) A novel crystalline form of disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-D]- pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid salt and processes therefor
AU2001229679A1 (en) Reduced form of coenzyme q in high bioavailability stable dosage forms and related applications
HK1081527A1 (en) Processes for the preparation of 4-[4-[4-(2-cyanoethenyl)-2,6- dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
NO2014030I1 (no) (E)-4-[[4-[[4-(2-cyanoetenyl)-2,6-dimetylfenyl]-amino]-2-pyrimidinyl]-amino]-benzonitril("Rilpivirine") samt enhver terapeutisk form derav som er dekket av det aktuelle patentet så som farmasøytisk akseptable salter av Rilpivirie innbefattende hydrokloridsaltet av Rilpivirine, og emtricitabine.
PT1155015E (pt) Processo para a preparação de (e)-(6-¬2-¬4-(4-fluorofenil)-6- isopropil-2-¬metil(metilsulfonil)amino pirimidin-5-il vinil(4r,6s)-2,2-dimetil¬1,3 dioxan-4-il)acetato de terc-butilo
HUP0400692A3 (en) Substituted 7h-pyrrolo[2,3-d]pyrimidine derivatives, their use and pharmaceutical compositions containing them
EE05332B1 (et) 3-{(3R,4R)-4-metl-3-[metl(7H-prrolo[2,3-d]primidiin-4-l)amino]piperidiin-1 -l}-3-oksopropionitriil, selle farmatseutiliselt vastuv?etav sool ja nende kasutamine
HUP0303350A3 (en) Use of substituted imidazo[1,2-a]pyridine-, imidazo[1,2-a]pyrimidine and imidazo[1,2-a]pyrazine-3-yl-amine derivatives for producing nos-inhibiting pharmaceutical compositions
AU9473601A (en) Stable solid dosage forms of amino acids and processes for producing same
AU2001282986A1 (en) The protein kinase domain of the large subunit of herpes simplex type 2 ribonucleotide reductase (icp10pk) has anti-apoptopic activity
PL363077A1 (en) Use of pyrazolo[4,3-d]pyrimidines
IL150403A0 (en) NOVEL PROCESS FOR THE PREPARATION OF α-(2-4-DISULFOPHENYL)-N-TERT-BUTYLNITRONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
PL361890A1 (en) Use of pyrazolo[4,3-d]pyrimidines
IL157061A (en) Process and intermediates for the preparation of (3-cyano-1h-indol-7-yl) (4-(4-fluorophenethyl)piperazin -1-yl)-methanone and salts thereof
IL150402A0 (en) NOVEL PROCESS FOR THE PREPARATION OF α-(2-4-DISULFOPHENYL)-N-TERT-BUTYLNITRONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
AU2001296746A1 (en) Oral dosage forms for administration of the combination of tegafur, uracil, folinic acid, and irinotecan and method of using the same
PL337788A1 (en) Method of obtaining 1-{[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1h-pyrazole[3,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulphonyl}-4-methylpiperazine
AU2002230022A1 (en) Salts of pyrimidine derivatives for use against coronary heart disease and atherosclerose
IL140127A0 (en) Process for the preparation of optically active 1,4-benzodixoane-2-carboxylic acid and derivatives thereof
AU2002220698A1 (en) Regulation of human fatty acid coa ligase
SI1265856T1 (en) Novel process for the preparation of alpha-(2-4-disulfophenyl)-n-tert-butylnitrone and pharmaceutically acceptable salts thereof
HK1090046A1 (en) Tetrahydro-4h-pyrido [1, 2-a]pyrimidines and related compounds useful as hiv integrase inhibitors
AU2002302635A1 (en) Process for the fermentative preparation of d-pantothenic acid and/or salts thereof
AU2002255007A1 (en) Process for the fermentative preparation of d-pantothenic acid and/or salts thereof

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed